Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.45 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.45 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL450221 | 0.88 | STS (0.52) | STSGPR119PDE4APDE4BPDE4C | |
| SCHEMBL30272599 | 0.87 | STS (0.51) | STSGPR119P2RX3P2RX2PDE4A | |
| SCHEMBL21722812 | 0.87 | STS (0.51) | STSGPR119P2RX3P2RX2PDE4A | |
| SCHEMBL9894017 | 0.85 | STS (0.49) | STSGPR119P2RX3P2RX2PDE4A | |
| SCHEMBL6121545 | 0.84 | STS (0.53) | STSGPR119MEN1KMT2AP2RX3 | |
| SCHEMBL18927006 | 0.84 | MEN1 (0.53) | STSGPR119MEN1KMT2ANPBWR1 | |
| SCHEMBL6036543 | 0.84 | EPHX2 (0.57) | STSGPR119MEN1KMT2AHRH3 | |
| SCHEMBL6122434 | 0.84 | GPR119 (0.48) | STSGPR119PDE4APDE4BPDE4C | |
| SCHEMBL447218 | 0.84 | GPR119 (0.48) | STSGPR119P2RX3P2RX2PDE4A | |
| SCHEMBL5538341 | 0.83 | GPR119 (0.63) | STSGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | STS 1000/4885GPR119 205/4885MEN1 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.